Plain-English translation of NCT04965675 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a new intravenous medication, can help prevent chronic migraines in teenagers. Chronic migraine means having headaches on 15 or more days per month, with at least 8 of those being migraines. The study will compare the medication at two different doses against a placebo (a non-active infusion) to see which works best and is safest.
Chronic migraine is a serious condition that affects many teenagers and can interfere with school, activities, and quality of life. This medication is designed to work in a new way to prevent migraines before they start, and researchers want to find out if it's safe and effective for young people.
You likely qualify if…
You likely don't qualify if…
The study lasts 24 weeks total. First, you'll have a 4-week screening period where you track your headaches daily on a device to confirm you qualify. Then you'll receive a single intravenous infusion (either the medication at a higher dose, the medication at a lower dose, or a placebo—decided by chance) during a visit. You won't know which one you're getting, and neither will the researchers. After that, you'll be monitored for 12 weeks with follow-up visits, and then for an additional 8 weeks for safety monitoring.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States